Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 30, 2019 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted...
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
August 29, 2019 07:30 ET
|
Esperion Therapeutics, Inc.
— Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —— Provided 25% hsCRP Reduction —— No Worsening of Glycemic Control —— Overall Adverse Events...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
August 08, 2019 07:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the second quarter ended June...
Esperion to Present at the BTIG Biotechnology Conference
August 06, 2019 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in a lipid panel discussion with investors at the BTIG Biotechnology...
Esperion to Report Second Quarter 2019 Financial Results August 8, 2019
July 30, 2019 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets...
Esperion and Oberland Capital Announce $200 Million Funding Agreement
June 26, 2019 16:10 ET
|
Esperion Therapeutics, Inc.
- $125 Million Upfront, $25 Million Upon FDA Approval, and $50 Million at Esperion’s Option After Launch -- Initial Mid-Single Digit Repayment Rate on U.S. Revenue to Step Down to Less than One...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results
May 08, 2019 07:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the first quarter ended March...
Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
January 03, 2018 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Wednesday, January 10, 2018 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time ANN ARBOR, Mich., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc....
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
December 14, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 01, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...